Literature DB >> 19827050

Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.

Nagalakshmi Nadiminty1, Smitha Dutt, Clifford Tepper, Allen C Gao.   

Abstract

PURPOSE: Our previous studies showed that NF-kappaB2/p52 is involved in the castration-resistant growth of the androgen-sensitive LNCaP prostate cancer cells. The role of NF-kappaB2/p52 in lymphomagenesis has been studied extensively, but its target genes in other cancers remain unknown. In order to identify genes potentially regulated by p52 in prostate cancer cells, we performed a genome-wide microarray analysis of genes differentially up- or down-regulated by the overexpression of p52 by adenoviral-mediated gene delivery in LNCaP cells. EXPERIMENTAL
DESIGN: Total RNAs from vector control-infected and Adeno-p52-infected LNCaP cells were used to prepare cDNAs, which were hybridized to the Whole Genome Human 44k Microarray chips (Agilent Technologies). Data analysis was performed using GeneSpring and Ingenuity Pathway Analysis software. Validation of microarray results was performed by real-time quantitative RT-PCR and Western blot analyses.
RESULTS: Expression of approximately 130 genes was differentially upregulated by >5-fold, whereas approximately 60 genes were differentially downregulated by >2-fold in p52-expressing LNCaP cells. Pathway analysis revealed that the upregulated genes belong to functional categories like cell growth and proliferation, cellular movement, cell-to-cell signaling and interaction, cancer, cell cycle, etc., whereas the downregulated genes were represented by functional categories like cell movement, antigen presentation, and cell death. Six of the top upregulated genes including annexin A2, PLAU, RND3, Twist2, VEGFC, and CXCL1 were validated by real-time PCR and Western blot analysis.
CONCLUSIONS: This study provides a comprehensive analysis of genes potentially regulated by NF-kappaB2/p52 in the LNCaP prostate cancer cell line and provides a rationale for the induction of castration-resistant growth by p52 in LNCaP cells. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19827050     DOI: 10.1002/pros.21062

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  18 in total

Review 1.  Pathophysiological Functions of Rnd3/RhoE.

Authors:  Wei Jie; Kelsey C Andrade; Xi Lin; Xiangsheng Yang; Xiaojing Yue; Jiang Chang
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

Review 2.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

3.  Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.

Authors:  Yuanyuan Cui; Nagalakshmi Nadiminty; Chengfei Liu; Wei Lou; Chad T Schwartz; Allen C Gao
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

4.  Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Meng Sun; Jun Chen; Jiao Yue; Hsing-Jien Kung; Christopher P Evans; Qinghua Zhou; Allen C Gao
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

5.  Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.

Authors:  Catherine Vaughan; Lathika Mohanraj; Shilpa Singh; Catherine I Dumur; Mahesh Ramamoorthy; Carleton T Garrett; Brad Windle; W Andrew Yeudall; Sumitra Deb; Swati Palit Deb
Journal:  Genes Cancer       Date:  2011-10

6.  MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.

Authors:  Nagalakshmi Nadiminty; Ramakumar Tummala; Wei Lou; Yezi Zhu; Jin Zhang; Xinbin Chen; Ralph W eVere White; Hsing-Jien Kung; Christopher P Evans; Allen C Gao
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

7.  Lin28 promotes growth of prostate cancer cells and activates the androgen receptor.

Authors:  Ramakumar Tummala; Nagalakshmi Nadiminty; Wei Lou; Yezi Zhu; Regina Gandour-Edwards; Hong-Wu Chen; Christopher P Evans; Allen C Gao
Journal:  Am J Pathol       Date:  2013-07       Impact factor: 4.307

Review 8.  Mechanism of lymph node metastasis in prostate cancer.

Authors:  Kaustubh Datta; Michael Muders; Heyu Zhang; Donald J Tindall
Journal:  Future Oncol       Date:  2010-05       Impact factor: 3.404

9.  PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention.

Authors:  Sheng Yao; Alix Bee; Daniel Brewer; Andrew Dodson; Carol Beesley; Youqiang Ke; Laurence Ambroisine; Gabrielle Fisher; Heinrich Møller; Tim Dickinson; Patricia Gerard; Lu-Yu Lian; Janet Risk; Brian Lane; Paul Smith; Victor Reuter; Daniel Berney; Christine Gosden; Peter Scardino; Jack Cuzick; Mustafa B A Djamgoz; Colin Cooper; Christopher S Foster
Journal:  Genes Cancer       Date:  2010-05

10.  NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Authors:  Nagalakshmi Nadiminty; Ramakumar Tummala; Chengfei Liu; Joy Yang; Wei Lou; Christopher P Evans; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2013-05-22       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.